Other Content

An error appeared in the article, “Managing cancer pain: Frequently asked questions,” in the July 2011 issue (Induru RR, Lagman RL. Managing cancer pain: Frequently asked questions. Cleve Clin J Med 2011; 78:449–464). On page 456, the fourth line of the right-hand column, “N-methyl-d-acetate” is incorrect. It should read “N-methyl-d-aspartate.” The error has been corrected in the online version of the article.

An error appeared in the article, “Managing cancer pain: Frequently asked questions,” in the July 2011 issue (Induru RR, Lagman RL. Managing cancer pain: Frequently asked questions. Cleve Clin J Med 2011; 78:449–464). On page 456, the fourth line of the right-hand column, “N-methyl-d-acetate” is incorrect. It should read “N-methyl-d-aspartate.” The error has been corrected in the online version of the article.

An error appeared in the article, “Managing cancer pain: Frequently asked questions,” in the July 2011 issue (Induru RR, Lagman RL. Managing cancer pain: Frequently asked questions. Cleve Clin J Med 2011; 78:449–464). On page 456, the fourth line of the right-hand column, “N-methyl-d-acetate” is incorrect. It should read “N-methyl-d-aspartate.” The error has been corrected in the online version of the article.

There were several errors in the citation of sources for figures in: Modrykamien A, Chat-burn RL, Ashton RW. Airway pressure release ventilation: An alternative mode of mechanical ventilation in acute respiratory distress syndrome. Cleve Clin J Med 2011; 78:101–110.

For Figure 1, the credit line was omitted. It should be: Reprinted from Papadakos PJ, Lachmann B. The open lung concept of mechanical ventilation: the role of recruitment and stabilization. Crit Care Clin 2007; 23:241–250, with permission from Elsevier.

Figure 2 and Figure 3 were correctly identified as being reprinted from Frawley PM, Habashi NM. Airway pressure release ventilation: theory and practice. AACN Clinical Issues 2001; 12:234–246. However, they were reprinted with permission from Wolters Kluwer Health/Lippincott, Williams & Wilkins, not from Elsevier.

The corrections have been made to the online versions of the article.

There were several errors in the citation of sources for figures in: Modrykamien A, Chat-burn RL, Ashton RW. Airway pressure release ventilation: An alternative mode of mechanical ventilation in acute respiratory distress syndrome. Cleve Clin J Med 2011; 78:101–110.

For Figure 1, the credit line was omitted. It should be: Reprinted from Papadakos PJ, Lachmann B. The open lung concept of mechanical ventilation: the role of recruitment and stabilization. Crit Care Clin 2007; 23:241–250, with permission from Elsevier.

Figure 2 and Figure 3 were correctly identified as being reprinted from Frawley PM, Habashi NM. Airway pressure release ventilation: theory and practice. AACN Clinical Issues 2001; 12:234–246. However, they were reprinted with permission from Wolters Kluwer Health/Lippincott, Williams & Wilkins, not from Elsevier.

The corrections have been made to the online versions of the article.

There were several errors in the citation of sources for figures in: Modrykamien A, Chat-burn RL, Ashton RW. Airway pressure release ventilation: An alternative mode of mechanical ventilation in acute respiratory distress syndrome. Cleve Clin J Med 2011; 78:101–110.

For Figure 1, the credit line was omitted. It should be: Reprinted from Papadakos PJ, Lachmann B. The open lung concept of mechanical ventilation: the role of recruitment and stabilization. Crit Care Clin 2007; 23:241–250, with permission from Elsevier.

Figure 2 and Figure 3 were correctly identified as being reprinted from Frawley PM, Habashi NM. Airway pressure release ventilation: theory and practice. AACN Clinical Issues 2001; 12:234–246. However, they were reprinted with permission from Wolters Kluwer Health/Lippincott, Williams & Wilkins, not from Elsevier.

The corrections have been made to the online versions of the article.

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2010. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2010. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2010. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

The last three references cited were numbered incorrectly in the body of the article El-Zawawy H, Mandell BF. Managing gout: How is it different in patients with chronic kidney disease? Cleve Clin J Med 2010; 77:919–928. A corrected version of the relevant section, which appeared on page 927, is included below. In addition, we failed to mention that Dr. El-Zawawy is an Assistant Professor of Medicine at the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. A corrected version has been posted on the Journal’s web site.

DOES URATE-LOWERING THERAPY HAVE BENEFITS BEYOND GOUT?

Despite experimental animal data and a strong epidemiologic association between hyperuricemia and hypertension,⁴⁶ metabolic syndrome, and rates of cardiovascular and all-cause mortality,⁴⁷ the evidence from interventional trials so far does not support the routine use of hypouricemic therapy to prevent these outcomes.

Similarly, hyperuricemia has long been associated with renal disease, and there has been debate as to whether hyperuricemia is a result of kidney dysfunction or a contributing factor.^46,48–51 A few studies have documented improvement of renal function after initiation of hypouricemic therapy.⁵² However, treating asymptomatic hyperuricemia to preserve kidney function remains controversial.

A recent study indicates that lowering the serum urate level with allopurinol can lower the blood pressure in hyperuricemic adolescents who have newly diagnosed primary hypertension.⁵³ This does not indicate, however, that initiating hypouricemic therapy in patients with preexisting, long-standing hypertension will be successful.

The last three references cited were numbered incorrectly in the body of the article El-Zawawy H, Mandell BF. Managing gout: How is it different in patients with chronic kidney disease? Cleve Clin J Med 2010; 77:919–928. A corrected version of the relevant section, which appeared on page 927, is included below. In addition, we failed to mention that Dr. El-Zawawy is an Assistant Professor of Medicine at the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. A corrected version has been posted on the Journal’s web site.

DOES URATE-LOWERING THERAPY HAVE BENEFITS BEYOND GOUT?

Despite experimental animal data and a strong epidemiologic association between hyperuricemia and hypertension,⁴⁶ metabolic syndrome, and rates of cardiovascular and all-cause mortality,⁴⁷ the evidence from interventional trials so far does not support the routine use of hypouricemic therapy to prevent these outcomes.

Similarly, hyperuricemia has long been associated with renal disease, and there has been debate as to whether hyperuricemia is a result of kidney dysfunction or a contributing factor.^46,48–51 A few studies have documented improvement of renal function after initiation of hypouricemic therapy.⁵² However, treating asymptomatic hyperuricemia to preserve kidney function remains controversial.

A recent study indicates that lowering the serum urate level with allopurinol can lower the blood pressure in hyperuricemic adolescents who have newly diagnosed primary hypertension.⁵³ This does not indicate, however, that initiating hypouricemic therapy in patients with preexisting, long-standing hypertension will be successful.

The last three references cited were numbered incorrectly in the body of the article El-Zawawy H, Mandell BF. Managing gout: How is it different in patients with chronic kidney disease? Cleve Clin J Med 2010; 77:919–928. A corrected version of the relevant section, which appeared on page 927, is included below. In addition, we failed to mention that Dr. El-Zawawy is an Assistant Professor of Medicine at the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. A corrected version has been posted on the Journal’s web site.

DOES URATE-LOWERING THERAPY HAVE BENEFITS BEYOND GOUT?

Despite experimental animal data and a strong epidemiologic association between hyperuricemia and hypertension,⁴⁶ metabolic syndrome, and rates of cardiovascular and all-cause mortality,⁴⁷ the evidence from interventional trials so far does not support the routine use of hypouricemic therapy to prevent these outcomes.

Similarly, hyperuricemia has long been associated with renal disease, and there has been debate as to whether hyperuricemia is a result of kidney dysfunction or a contributing factor.^46,48–51 A few studies have documented improvement of renal function after initiation of hypouricemic therapy.⁵² However, treating asymptomatic hyperuricemia to preserve kidney function remains controversial.

A recent study indicates that lowering the serum urate level with allopurinol can lower the blood pressure in hyperuricemic adolescents who have newly diagnosed primary hypertension.⁵³ This does not indicate, however, that initiating hypouricemic therapy in patients with preexisting, long-standing hypertension will be successful.

A typographical error appeared in: Samplaski MK, Irwin BH, Desai M. Less-invasive ways to remove stones from the kidneys and ureters. Cleve Clin J Med 2009; 76:592–598. On page 594, second column, fourth paragraph, the text should read, “Lithotripsy is more likely to fail if the skin-to-stone distance is more than 10 cm…”—not 10 mm.

A typographical error appeared in: Samplaski MK, Irwin BH, Desai M. Less-invasive ways to remove stones from the kidneys and ureters. Cleve Clin J Med 2009; 76:592–598. On page 594, second column, fourth paragraph, the text should read, “Lithotripsy is more likely to fail if the skin-to-stone distance is more than 10 cm…”—not 10 mm.

A typographical error appeared in: Samplaski MK, Irwin BH, Desai M. Less-invasive ways to remove stones from the kidneys and ureters. Cleve Clin J Med 2009; 76:592–598. On page 594, second column, fourth paragraph, the text should read, “Lithotripsy is more likely to fail if the skin-to-stone distance is more than 10 cm…”—not 10 mm.

An incorrect brand name was used for a formulation of methyprednisolone in: Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: Diagnosing it and finding the cause Cleve Clin J Med 2008; 75:258–280; doi:10.3949/ccjm.75.4.258. On page 275, in the section on treatment, the second paragraph should read:

“Most experts recommend intravenous methylprednisolone (Solu-Medrol) (up to 500 mg every 6 hours, although lower doses seem to have similar efficacy) for 4 or 5 days, followed by a gradual taper to maintenance doses of oral steroids.”

The online versions of this article have been corrected.

An incorrect brand name was used for a formulation of methyprednisolone in: Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: Diagnosing it and finding the cause Cleve Clin J Med 2008; 75:258–280; doi:10.3949/ccjm.75.4.258. On page 275, in the section on treatment, the second paragraph should read:

“Most experts recommend intravenous methylprednisolone (Solu-Medrol) (up to 500 mg every 6 hours, although lower doses seem to have similar efficacy) for 4 or 5 days, followed by a gradual taper to maintenance doses of oral steroids.”

The online versions of this article have been corrected.

An incorrect brand name was used for a formulation of methyprednisolone in: Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: Diagnosing it and finding the cause Cleve Clin J Med 2008; 75:258–280; doi:10.3949/ccjm.75.4.258. On page 275, in the section on treatment, the second paragraph should read:

“Most experts recommend intravenous methylprednisolone (Solu-Medrol) (up to 500 mg every 6 hours, although lower doses seem to have similar efficacy) for 4 or 5 days, followed by a gradual taper to maintenance doses of oral steroids.”

The online versions of this article have been corrected.

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine for the year ending December 31, 2009. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine for the year ending December 31, 2009. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine for the year ending December 31, 2009. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief